Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cartigel is a combination pharmaceutical product developed and marketed by Laboratorio Pharmedic, a generic pharmaceutical company based in Central America. The product contains two primary active ingredients: glucosamine sulfate and chondroitin sulfate. These substances are naturally occurring components of articular cartilage and are used therapeutically to manage symptoms of osteoarthritis and other degenerative joint diseases. Glucosamine serves as a metabolic precursor for the synthesis of glycosaminoglycans and proteoglycans, which are essential for cartilage repair and maintenance. Chondroitin sulfate provides structural integrity to the cartilage by promoting water retention and elasticity, while also inhibiting degradative enzymes that break down the joint matrix. Cartigel is typically administered orally to reduce joint pain, improve mobility, and potentially slow the progression of cartilage degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucosamine sulfate + chondroitin sulfate (Laboratorios Pharmedic).